Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 16:7:47.
doi: 10.3389/fphys.2016.00047. eCollection 2016.

Promising Therapy Candidates for Liver Fibrosis

Ping Wang  1 , Yukinori Koyama  2 , Xiao Liu  3 , Jun Xu  3 , Hsiao-Yen Ma  3 , Shuang Liang  3 , In H Kim  3 , David A Brenner  4 , Tatiana Kisseleva  5
Affiliations
Review

Promising Therapy Candidates for Liver Fibrosis

Ping Wang et al. Front Physiol. .

Abstract

Liver fibrosis is a wound-healing process in response to repeated and chronic injury to hepatocytes and/or cholangiocytes. Ongoing hepatocyte apoptosis or necrosis lead to increase in ROS production and decrease in antioxidant activity, which recruits inflammatory cells from the blood and activate hepatic stellate cells (HSCs) changing to myofibroblasts. Injury to cholangiocytes also recruits inflammatory cells to the liver and activates portal fibroblasts in the portal area, which release molecules to activate and amplify cholangiocytes. No matter what origin of myofibroblasts, either HSCs or portal fibroblasts, they share similar characteristics, including being positive for α-smooth muscle actin and producing extracellular matrix. Based on the extensive pathogenesis knowledge of liver fibrosis, therapeutic strategies have been designed to target each step of this process, including hepatocyte apoptosis, cholangiocyte proliferation, inflammation, and activation of myofibroblasts to deposit extracellular matrix, yet the current therapies are still in early-phase clinical development. There is an urgent need to translate the molecular mechanism of liver fibrosis to effective and potent reagents or therapies in human.

Keywords: cholangiocyte; early-phase clinical trial; hepatocytes; inflammation; liver fibrosis; myofibroblasts.

PubMed Disclaimer

References

    1. Anstee Q. M., Concas D., Kudo H., Levene A., Pollard J., Charlton P., et al. . (2010). Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 53, 542–550. 10.1016/j.jhep.2010.03.016 - DOI - PubMed
    1. Aoyama T., Paik Y. H., Watanabe S., Laleu B., Gaggini F., Fioraso-Cartier L., et al. . (2012). Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56, 2316–2327. 10.1002/hep.25938 - DOI - PMC - PubMed
    1. Barreyro F. J., Holod S., Finocchietto P. V., Camino A. M., Aquino J. B., Avagnina A., et al. . (2015). The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 35, 953–966. 10.1111/liv.12570 - DOI - PubMed
    1. Barry-Hamilton V., Spangler R., Marshall D., McCauley S., Rodriguez H. M., Oyasu M., et al. . (2010). Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009–1017. 10.1038/nm.2208 - DOI - PubMed
    1. Bettaieb A., Jiang J. X., Sasaki Y., Chao T. I., Kiss Z., Chen X., et al. . (2015). Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of Steatohepatitis in mice. Gastroenterology 149, 468.e10–480.e10. 10.1053/j.gastro.2015.04.009 - DOI - PMC - PubMed